We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+31.9%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$244M
AUM Growth
+$35.9M
Cap. Flow
-$9.96M
Cap. Flow %
-4.08%
Top 10 Hldgs %
93.11%
Holding
23
New
1
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$4.13M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$3.49M
3
ASND icon
Ascendis Pharma A/S
ASND
+$2.28M

Top Sells

Rank Stock Value
1
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$5.79M
2
HRTX icon
Heron Therapeutics
HRTX
+$5.32M
3
CTMX icon
CytomX Therapeutics
CTMX
+$3.8M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$1.79M
5
SYRE icon
Spyre Therapeutics
SYRE
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 91.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$78.7M 32.22%
1,035,657
– –
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$2.36B
$51M 20.87%
6,071,142
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$22.7M 9.3%
811,492
+90,340
+13% +$2.28M
PDSB icon
4
PDS Biotechnology
PDSB
$41.1M
$17.6M 7.21%
96,679
– –
RARX
5
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$15.4M 6.32%
725,029
+182,529
+34% +$3.49M
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.82M 3.2%
458,882
– –
SIOX
7
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.42M 2.63%
53,699
– –
CTMX icon
8
CytomX Therapeutics
CTMX
$788M
$4.99M 2.04%
288,915
-288,916
-50% -$3.8M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$4.15M 1.7%
+156,880
New +$4.13M
AKTX
10
Akari Therapeutics
AKTX
$19.3M
$4.09M 1.67%
462
– –
ORKA
11
Oruka Therapeutics
ORKA
$5.59B
$2.75M 1.13%
4,995
– –
CHRS icon
12
Coherus Oncology
CHRS
$216M
$2.02M 0.82%
95,276
-34,353
-27% -$845K
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$1.95M 0.8%
228,130
-87,850
-28% -$801K
LPCN icon
14
Lipocine
LPCN
$18.4M
$1.64M 0.67%
24,706
– –
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$1.64M 0.67%
221,651
– –
OCRX
16
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.59M 0.65%
1,217,872
– –
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$756K 0.31%
28,000
– –
ARCT icon
18
Arcturus Therapeutics
ARCT
$172M
$211K 0.09%
26,449
-193,189
-88% -$1.79M
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$200K 0.08%
3,270
– –
HRTX icon
20
Heron Therapeutics
HRTX
$89.1M
– –
-405,901
Closed -$5.32M
SYRE icon
21
Spyre Therapeutics
SYRE
$8.7B
– –
-14,005
Closed -$1.52M
CLCD
22
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-159,110
Closed -$5.79M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q1 2017 Portfolio in Review

As of Q1 2017, VHCP Management II held 23 positions worth $244M, up 17% from $208M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

VHCP Management II withdrew a net $9.96M in Q1 2017, closing 3 positions and reducing 4 holdings. Its most notable exit was CoLucid Pharmaceuticals, Inc., an estimated $5.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier.

Against the trend, VHCP Management II opened a new position in Acceleron Pharma worth $4.15M.

  • VHCP Management II's largest Q1 2017 buy was Acceleron Pharma: 156,880 shares worth $4.15M.
  • VHCP Management II added most to Ra Pharmaceuticals, Inc. Common Stock in Q1 2017, an estimated $3.49M increase.
  • VHCP Management II's biggest Q1 2017 reduction was CytomX Therapeutics, cutting an estimated $3.8M.
  • VHCP Management II fully exited CoLucid Pharmaceuticals, Inc. in Q1 2017, selling an estimated $5.79M.
  • VHCP Management II's ten largest holdings make up 93% of its $244M portfolio in Q1 2017.
  • VHCP Management II opened 1 new position and closed 3 in Q1 2017.
  • VHCP Management II's portfolio value rose 17% quarter-over-quarter to $244M.

Based on VHCP Management II's 13F filing for Q1 2017, filed 12 May 2017.